CureVac and GSK have been racing behind Moderna to try to get the first mRNA flu vaccine to market. But, now, the European partners have come up against the exact same problem as their U.S. competitor ...
As you might know, Moderna, Inc. (NASDAQ:MRNA) just kicked off its latest quarterly results with some very strong numbers. Moderna outperformed estimates, with revenues of US$1.0b beating estimates by ...
Food and Drug Administration officials say they will ratchet up requirements for vaccine studies, citing concerns about COVID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback